Lantern Pharma (NASDAQ: LTRN), a clinical-stage precision oncology company, announced its second-quarter 2026 operational and financial results, showcasing significant advancements in its AI-driven oncology pipeline and the strategic establishment of Open Medicine AI (OMAI) as a wholly owned subsidiary. The company reported promising emerging data from its Phase 2 HARMONIC trial, indicating that LP-300's progression-free survival benefit deepened with treatment duration in patients with EGFR exon 21 L858R mutations. Additionally, the U.S. Food and Drug Administration (FDA) reviewed key protocol amendments without objection, potentially accelerating the drug's development.
In regulatory news, the European Medicines Agency (EMA) cleared an investigator-initiated Phase 1b/2 trial of LP-184, also known as zirdafulven, in biomarker-selected advanced bladder cancer. Concurrently, the U.S. Patent and Trademark Office (USPTO) issued a Notice of Allowance for a three-gene patient-selection signature for LP-184, strengthening the company's intellectual property portfolio. These milestones underscore Lantern's focus on developing targeted therapies for patients with specific genetic profiles.
Financially, Lantern reported a loss from operations of approximately $3.5 million in the second quarter, a 25% improvement from the $4.7 million loss in the same period last year. Research and development expenses declined by 42% to approximately $1.8 million, reflecting increased efficiency. Net loss widened to approximately $7.1 million, or $0.57 per share, compared to $4.3 million, or $0.40 per share, a year earlier, largely due to approximately $3.6 million in warrant-related expenses. The company maintains cash, cash equivalents, and marketable securities totaling approximately $7.4 million as of June 30, 2026.
A notable development in August was the establishment of Open Medicine AI (OMAI) as a separate company, with board-approved commercial licensing agreements for the multi-agentic AI co-scientist platform previously launched as withZeta.ai. This platform is now commercially available as a subscription-based research tool for the global biomedical and drug development community, representing a new revenue stream for Lantern. The move underscores Lantern's commitment to leveraging AI beyond its internal pipeline, offering its proprietary technology to external researchers and organizations.
Lantern Pharma continues to leverage its proprietary RADR platform, which uses AI and machine learning to transform cancer therapy development. The company's clinical pipeline includes LP-184, LP-284, and LP-300, with LP-184 also being developed for pediatric CNS cancers through Starlight Therapeutics, a wholly owned subsidiary focused on CNS malignancies. Lantern operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas.
These advancements highlight Lantern's strategic focus on precision oncology and AI-driven drug development, positioning the company to potentially address significant unmet medical needs in cancer treatment. The establishment of OMAI and the commercial availability of withZeta.ai could provide additional growth opportunities beyond traditional drug development.
